GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beijing SL Pharmaceutical Co 002038.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

5.10

-0.97%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Beijing SL Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 002038.SZ. It has been listed since 9 September 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥623.6m and a net loss of CN¥347.2m. At that date it held total assets of CN¥6.07bn and shareholders' equity of CN¥5.18bn.

Beijing SL Pharmaceutical Co., Ltd. engages in the development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2004-09-09. The firm's main products include complex coenzyme, arsenic trioxide, recombinant human granulocyte stimulating factor, recombinant human interleukin-2, recombinant human basic fibroblast growth factor, thymopentin, enoxaparin and Xingling dropping pills, among others. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
9 Sept 2004
Employees
757

Leadership

Pay as last reported

  • Mr. Mingbo XuChairman of the Board, General Manager, since 2004CN¥385,000
  • Ms. Li JiFinance DirectorCN¥322,400
  • Ms. Shujie LiangSecretary of the Board, Director, since 2003CN¥526,400
  • Mr. Yulin ChenDirector, since 1994CN¥50,000
  • Mr. Jiaqi ZhangDirector
  • Ms. Longyun ChengIndependent DirectorCN¥50,000
  • Ms. Lingjia QianIndependent DirectorCN¥50,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
38
Environment
33
Social
30
Governance
51
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Beijing SL Pharmaceutical develops complex coenzyme for domestic market distribution.
  • The company's recombinant human granulocyte stimulating factor is a key product in Health Care sector.
  • Beijing SL Pharmaceutical employs 757 full-time employees in Biotechnology industry.

Weaknesses

  • Beijing SL Pharmaceutical's products are distributed only in domestic and overseas markets.
  • The company's main products include arsenic trioxide, which has limited market appeal.
  • Beijing SL Pharmaceutical has no mention of international expansion plans in facts.

Opportunities

  • Beijing SL Pharmaceutical can expand recombinant human interleukin-2 to new markets.
  • The firm's recombinant human basic fibroblast growth factor has potential in Health Care.
  • Beijing SL Pharmaceutical can leverage enoxaparin for global market growth.

Threats

  • Beijing SL Pharmaceutical faces competition from domestic Biotechnology firms.
  • The company's reliance on arsenic trioxide may pose health risks.
  • Beijing SL Pharmaceutical's products are limited to domestic and overseas markets only.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.